Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov-Dec;17(6):e374-e381.
doi: 10.1097/ADM.0000000000001213. Epub 2023 Aug 11.

Real-world Evidence for Impact of Opioid Agonist Therapy on Nonfatal Overdose in Patients with Opioid Use Disorder during the COVID-19 Pandemic

Kenneth Lee  1 , Yue Zhao, Tazmin Merali, Christopher Fraser, Jan-Marie Kozicky, Marie-Christine Mormont, Brian Conway
Affiliations

Real-world Evidence for Impact of Opioid Agonist Therapy on Nonfatal Overdose in Patients with Opioid Use Disorder during the COVID-19 Pandemic

Kenneth Lee et al. J Addict Med. 2023 Nov-Dec.

Erratum in

Abstract

Objectives: The primary objectives of this study were to describe the demographics and clinical characteristics of patients who were treated with buprenorphine extended-release versus buprenorphine-naloxone sublingual tablets versus methadone in a real-world setting and to evaluate the difference in nonfatal overdose events between treatment cohorts.

Methods: This study was a retrospective chart review of patients with opioid use disorder initiating opioid agonist therapy in Canada during the outset of the COVID-19 pandemic (March 11, 2020 to October 31, 2021). Three treatment cohorts were defined by the initial prescribed opioid agonist therapy regimen: buprenorphine extended-release, buprenorphine-naloxone sublingual tablets, and methadone. Baseline characteristics, as well as treatment status, overdose events, and substance use 6 months after treatment initiation were collected using a standardized form.

Results: Nine clinics provided data on 379 patient cases. The incidence rate (number of events per 100 person-years) for a self-reported nonfatal overdose was 46.8 (n = 18), 19.3 (n = 10), and 1.7 (n = 1) in the methadone, buprenorphine-naloxone sublingual tablets, and buprenorphine extended-release cohorts, respectively. The risk-adjusted difference for the proportion of patients with nonfatal overdose was 8.59% (95% confidence interval, 3.10-14.08%; P = 0.0022) for methadone versus buprenorphine extended-release and 6.51% (95% confidence interval, 1.46-11.56%; P = 0.0115) for buprenorphine-naloxone sublingual tablets versus buprenorphine extended-release.

Conclusions: Buprenorphine extended-release was associated with lower rates of nonfatal overdose events compared with daily opioid agonist therapy. Given the limitations of this naturalistic, retrospective design, further prospective studies are needed to validate these findings and demonstrate the potential for long-acting opioid agonist therapy in addressing the opioid crisis.

PubMed Disclaimer

References

    1. Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioid- and stimulant-related harms in Canada. Ottawa: Public Health Agency of Canada; March 2023. Accessed 2023 May 15. Available from: https://health-infobase.canada.ca/substance-related-harms/opioids-stimul... .
    1. Simha S, Ahmed Y, Brummett CM, et al. Impact of the COVID-19 pandemic on opioid overdose and other adverse events in the USA and Canada: A systematic review. Reg Anesth Pain Med . 2023;48(1):37–43.
    1. Results from samples checked by Toronto’s drug checking service: April 24 – May 7, 2021. Toronto: Toronto’s Drug Checking Service, 2021: [cited 2022 Oct 10]. Available from: https://drugchecking.cdpe.org/report/april-24-may-7-2021 .
    1. Illicit Drug Toxicity Deaths in BC. January 1, 2012 – August 31, 2021. Vancouver: BC Coroners Service, 2021: [cited 2022 Sept 28]. Available from: https://www2.gov.bc.ca/assets/gov/birth-adoption-death-marriage-and-divo... .
    1. Friesen EL, Kurdyak PA, Gomes T, et al. The impact of the COVID-19 pandemic on opioid-related harm in Ontario. Science Briefs of the Ontario COVID-19 Science Advisory Table . 2021;2(42). doi:https://doi.org/10.47326/ocsat.2021.02.42.1.0. - DOI